Pharmaceutical & Drug Policy
Comments on biosimilar streamlining efforts and context on commercial barriers to competition
Pharmaceutical & Drug Policy
Rethinking Medicare’s bundled payment model for opioid treatment programs
Pharmaceutical & Drug Policy
What earnings calls and SEC filings reveal about the state of pharma
Pharmaceutical & Drug Policy
When cheap becomes fragile: How the race to the bottom in generics undermines manufacturing quality and what to do about it
Experts
Ryan Conrad
Visiting Fellow
- Economic Studies, Center on Health Policy
Vanda Felbab-Brown
Director
- Initiative on Nonstate Armed Actors,
Co-Director
- Africa Security Initiative,
Senior Fellow
- Foreign Policy, Strobe Talbott Center for Security, Strategy, and Technology